NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-211-2020-0-CA-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER CA National Stage 3193855 Pending
NCI E-189-2020-1-US-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION US National Stage 18/027,981 Pending
NIAID E-039-2023-0-US-01 SARS-COV-2 SPIKE FUSED TO HEPATITIS B SURFACE ANTIGEN US 63/454,276 Abandoned
NIAID E-039-2023-1-US-01 HEPATITIS B SURFACE ANTIGEN-BASED NANOPARTICLE IMMUNOGENS OF SARS-COV-2 VARIANT SPIKE US 63/454,279 Abandoned
NCI E-173-2020-0-GB-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 GB National Stage 2304187.4 Abandoned
NIDDK E-086-2022-0-EP-01 METHOD AND SYSTEM FOR SYNCHRONIZING A ROTATIONAL ECCENTRIC MASS WITH A MAGNETIC RESONANCE ELASTOGRAPHY SCAN EP EP 23163001.3 Pending
NIAID E-153-2019-1-HK-15 MUMPS AND MEASLES VIRUS IMMUNOGENS AND THEIR USE HK National Stage 62023070225.5 Pending
NCI E-032-2022-0-US-01 SYNNOTCH CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF US 63/491,208 Expired
NIDCR E-107-2022-1-JP-01 TREATMENT METHODS OF TRIPHENYL CALCILYTIC COMPOUNDS JP National Stage 2023-518198 Pending
NIDA E-053-2023-0-US-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS US 63/452,879 Expired
NCATS E-041-2021-3-US-01 RALDH1 Inhibitors For The Immunotherapy Of Hepatocellular Carcinoma US 63/452,978 Expired
NEI E-131-2022-0-US-01 METHODS FOR TREATMENT OF AGE-RELATED
MACULAR DEGENERATION 		US 63/453,006 Expired
NIDCR E-094-2023-0-US-01 METHODS FOR PRODUCING STABLE HUMAN CHONDROCYTES AND THEIR USE US 63/490,759 Expired
NIAID E-166-2021-4-US-01 Coronavirus Antibodies And Uses Thereof US National Stage 18/026,544 Pending
NHGRI E-167-2020-0-US-02 NOVEL ADENO-ASSOCIATED VIRAL (AAV) VECTORS TO TREAT HEREDITARY METHYLMALONIC ACIDEMIA (MMA) CAUSED BY METHYLMALONYL-COA MUTASE
(MMUT) DEFICIENCY 		US National Stage 18/026,421 Pending
NCI E-036-2021-2-US-01 METHODS FOR TREATING INFECTIONS US National Stage 18/121,496 12374435 Issued PDF
NIAID E-166-2021-4-CA-01 Coronavirus Antibodies And Uses Thereof CA National Stage 3192706 Pending
NHLBI E-143-2021-1-CN-01 TISSUE CUTTING SYSTEMS AND METHODS CN National Stage 202180062140.X Pending
NIAID E-266-2023-0-EP-01 Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation EP ORD 23386021.2 Abandoned
NCI E-075-2022-0-PC-01 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES PCT PCT PCT/US2023/064047 Expired
NICHD E-198-2022-0-US-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH US 63/451,066 Expired
NIAAA E-189-2021-0-PCT-01 CANNABINOID RECEPTOR MODULATING COMPOUNDS PCT PCT PCT/US2023/014846 Expired
NCI E-165-2020-0-CN-01 HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation CN National Stage 202180061706.7 Pending
NCI E-109-2020-0-EP-01 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES EP National Stage 21769306.8 Pending
NCATS E-200-2020-0-EP-03 REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY EP National Stage 21773171.0 Pending
NCI E-167-2019-0-JP-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY JP National Stage 2023-515322 Pending
NIDA E-036-2023-0-US-01 Dual-Target Dopamine D3 (D3R) and -Opioid (MOR) Receptors Ligands as Potentially Safer Analgesics US 63/488,896 Expired
NCATS E-133-2020-1-US-01 METHODS AND SYSTEMS FORMANAGING FLUID FLOW INCONTAINERS US National Stage 18/044,179 12434172 Issued PDF
NHLBI E-124-2014-3-JP-02 Device For Closure Of Transvascular Or Transcameral Access Ports JP DIV 2023-033571 Issued
NCATS E-198-2016-0-US-02 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling US CON 18/117,735 Abandoned
NIAID E-052-2017-4-IL-01 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection IL DIV 2040-11-30 Abandoned
NCI E-173-2020-0-US-02 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 US National Stage 18/024,557 Pending
NCI E-173-2020-0-JP-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 JP National Stage 2023-515071 Pending
NIDDK E-110-2021-0-PCT-01 SYNTHETIC AMPHIPATHIC HELICAL PEPTIDES AND TREATMENT METHODS USING SYNTHETIC AMPHIP ATHIC HELICAL PEPTIDES PCT PCT PCT/US2023/063601 Expired
NCI E-167-2019-0-US-02 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY US National Stage 18/024,430 Pending
NIBIB E-139-2022-1-US-01 METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING US 63/488,122 Expired
NCI E-163-2020-0-CA-01 LZK-TARGETING DEGRADERS AND METHODS OF USE CA National Stage 3193736 Pending
NCI E-163-2020-0-US-02 LZK-TARGETING DEGRADERS AND METHODS OF USE US CIP 18/176,849 Pending
NIDDK E-001-2022-0-EP-01 Rotating Cylinder For MRE Devices EP EP 23159482.1 Pending
NCI E-282-2016-2-JP-02 Methods For Pre-conditioning Patients For Cell Therapy JP DIV 2023-030596 Pending
NHLBI E-143-2021-1-IL-01 TISSUE CUTTING SYSTEMS AND METHODS IL National Stage 2073-10-30 Pending
NHLBI E-126-2020-0-EP-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) EP National Stage 21862955.8 Pending
NCI E-163-2020-0-JP-01 LZK-TARGETING DEGRADERS AND METHODS OF USE JP National Stage 2023-513976 Pending
NIAID E-189-2023-0-KR-01 COMPOSITION FOR PREVENTING OR TREATING SYSTEMIC CAPILLARY LEAK SYNDROME KR ORD 10-2023-0027030 Pending
NCI E-173-2018-2-AU-01 Viral Methods Of T Cell Therapy AU DIV 2023201224 Pending
NCI E-173-2020-0-CA-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 CA National Stage 3191186 Pending
NCI E-167-2019-0-CA-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY CA National Stage 3191211 Pending
NCATS E-014-2022-0-US-02 HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF US National Stage 18/043,163 Pending
NCI E-149-2015-0-US-02 METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD US CON 18/174,928 Pending
NCATS E-204-2022-2-US-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF US 63/487,079 Expired